Parasetamol (Asetaminofen) Zehirlenmeleri
Synopsis
Parasetamol, dünyada ve Türkiye'de en yaygın kullanılan analjezik ve antipiretik ilaçlardan biri olup önerilen dozlarda güvenlidir; ancak aşırı doz alımlarında karaciğer ve böbrek hasarı ile seyreden ciddi zehirlenmelere yol açmaktadır. Normal dozlarda karaciğerde sülfasyon ve glukuronidasyon ile metabolize edilirken, yüksek dozlarda veya glutatyonun yetersiz kaldığı durumlarda reaktif bir metabolit olan NAPQI birikerek glutatyon depolarını tüketir. Tüketilen glutatyon sonucu biriken NAPQI, hücresel makromoleküllere kovalent bağlanarak oksidatif stres, DNA hasarı, sentrilobüler hepatik nekroz ve renal kortikal nekroza neden olur. Klinik seyir dört evreden oluşur: İlk 24 saatte asemptomatik veya hafif semptomlar görülürken, 24-72. saatlerde transaminazlar yükselir ve 72-96. saatlerde sarılık, koagülopati, ensefalopati ve ölüm riskiyle karakterize fulminan karaciğer yetmezliği gelişir. Tanıda hasta öyküsü, 4-24. saatlerde ölçülen serum parasetamol düzeylerinin Rumack-Matthew nomogramı ile değerlendirilmesi ve laboratuvar testleri esastır. Tedavi yaklaşımı hasta stabilizasyonu, gastrointestinal dekontaminasyon (gastrik lavaj, aktif kömür) ve temel antidot olan N-asetil sistein (NAC) uygulamasını kapsar. İlaç alımından sonraki ilk 8 saat içinde başlanan oral veya intravenöz NAC tedavisi karaciğer toksisitesine karşı tam koruyuculuk sağlar. Ağır vakalarda hemodiyaliz, yoğun bakım takibi ve Modifiye King's College kriterlerine göre karaciğer transplantasyonu değerlendirilmelidir.
Paracetamol is one of the most widely used analgesic and antipyretic drugs globally and in Turkey, and it is safe at recommended therapeutic doses; however, overdose ingestions lead to severe poisoning characterized by liver and kidney damage. While it is primarily metabolized in the liver via sulfation and glucuronidation at therapeutic doses, under overdose conditions or states of glutathione depletion, the accumulation of its reactive metabolite, NAPQI, depletes hepatic glutathione stores. The resulting uncleared NAPQI covalently binds to cellular macromolecules, causing oxidative stress, DNA damage, centrilobular hepatic necrosis, and renal cortical necrosis. The clinical course consists of four stages: patients are asymptomatic or present with minimal non-specific symptoms in the first 24 hours, experience elevated transaminases between 24 and 72 hours, and develop fulminant liver failure characterized by jaundice, coagulopathy, encephalopathy, and high mortality risk during 72 to 96 hours. Diagnosis relies on patient history, laboratory tests, and assessing serum paracetamol levels measured 4–24 hours post-ingestion against the Rumack-Matthew nomogram. Treatment includes patient stabilization, gastrointestinal decontamination (gastric lavage, activated charcoal), and administration of N-acetylcysteine (NAC) as the essential antidote. Oral or intravenous NAC therapy initiated within the first 8 hours provides complete protection against hepatotoxicity. In severe cases, hemodialysis may be required, and patients with acute liver failure should be monitored in intensive care and evaluated for liver transplantation according to Modified King's College criteria.
References
Emet, M., Yayla, M. Asetaminofen (Parasetamol) Zehirlenmesi. Türkiye Klinikleri J Emerg Med-Special Topics. 2016;2(1),51-7
Bertolini, A., Ferrari, A., Ottani, A., et al. Paracetamol : New vistas of an old drug. CNS. Drug. Rev. 2006;12(3-4), 250-275.
Prescott, LF. Paracetamol: past, present, and future. Am J Ther. 2000;7(2):143-7.
Özcan, N., İkincioğulları, D. Ulusal Zehir Danışma Merkezi 2008 Yılı Çalışma Raporu Özeti. Turk Hij Den Biyol Derg. 2009; 66(ER-3): 29-58.
Rotundo, L., Pyrsopoulos, N. Liver injury induced by paracetamol and challenges associated with intentional and unintentional use. World J Hepatol. 2020;12(4):125-136. doi:10.4254/wjh.v12.i4.125.
Sharma, C.V., Mehta, V. Paracetamol: mechanisms and updates. Continuing Education in Anaesthesia, Critical Care&Pain. 2014, 14(4), 153-158.
Eroğlu, M., Eyigör, S. Kronik Bel ve Boyun Ağrılı Hastada Temel Analjezikler. TOTBİD Dergisi 2017;16:126-132. Doi : 10.14292/totbid.dergisi.2017.20.
Smith, H.S. Potential analgesic mechanism of acetaminophen. Pain Physician 2009; 12(1): 269– 80.
Dougherty, P.P., Klein-Schwartz, W. Unexpected late rise in plasma acetaminophen concentrations with change in risk stratification in acute acetaminophen overdoses. J Emerg Med 2012;43(1):58-63.
Mazaleuskaya, L.L., Sangkuhl, K., Thorn, C.F., et al. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenetics and genomics.2015;25(8):416-26.
Eroğlu, S.E.(2016). Parasetamol (Asetaminofen) Zehirlenmeleri. Başar Cander (Ed.), Cander Acil Tıp : Temel Başvuru Kitabı Cilt-2 1. Baskı içinde (s.1911-1918). İstanbul : İstanbul Tıp Kitabevleri
Pillay, V.V.(2013). Modern Medical Toxicology. (Fourth Edition). New Delhi : Jaypee Brothers Medical Publishers (P) Ltd.
Karabağ Çoban, F., Kuru, B. Effect of boron on trace element level and oxidative stress in paracetamol induced hepatotoxicity model.Journal of Boron 2019;4(2),92-99. DOI: 10.30728/boron.518606.
Kartal, N., Ozbek-bi̇lgi̇n, A., Yüceli̇k, Ş., ve ark. Protective Effects of Agomelatin, a Melatonin Receptor Agonist, on Paracetamol Induced Nephrotoxicity.Hacettepe University Journal of the Faculty of Pharmacy, 2019;39(2),81-89.
Mazlum, A., Ceylan, B., Şişman, G. Parasetamolün Tedavi Edici Dozlarda Verilmesi Sonrası Hepatoselüler Hasar Gelişen Olgu. İstanbul Tıp Dergisi 2007;8(4):23-25
Wightman, R.S., Nelson, L.S.(2020). Acetaminophen. Judith E. Tintinalli (Ed.), Tintinalli's emergency medicine: A comprehensive study guide Nineth edition içinde (s.1252-1258). New York: McGraw-Hill Education.
Agrawal, S., Khazaeni, B. Acetaminophen Toxicity. StatPearls [Internet]. U.S. National Library of Medicine, November 20, 2020. https://www.ncbi.nlm.nih.gov/books/NBK441917/.
Saljoughian, M. Acetaminophen Intoxication : A Critical-Care Emergency. US Pharm. 2016;41(12):38-41.
Levine, M., Stellpflug, S.J., Pizon, A.F., et al. Hypoglycemia and lactic acidosis outperform King's College criteria for predicting death or transplant in acetaminophen toxic patients. Clin Toxicol (Phila). 2018;56(7):622-625.
Chun, L.J., Tong, M.J., Busuttil, R.W., et al. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gasteroenterol. 2009;43:342-349.
Rumack, B.H. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002;40(1):3-20.
Radke, J.B., Algren, D.A., Chenoweth, J.A., et al. Transaminase and Creatine Kinase Ratios for Differentiating Delayed Acetaminophen Overdose from Rhabdomyolysis. West J Emerg Med. 2018;19(4):731-736.
Bizovi, K.E., Aks, S.E., Paloucek, F., et al. Late increase in acetaminophen concentration after overdose of Tylenol Extended Relief. Ann. Emerg. Med. 1996;28:549–551.
James, L.P., Wells, E., Beard, R.H., et al. Predictors of outcome after acetaminophen poisoning in children and adolescents. J Pediatr. 2002 ;140(5):522-6. doi: 10.1067/mpd.2002.122936.
Tandoğan, M., Emektar. E., Dağar, S., ve ark. Acil Servise Parasetamol İntoksikasyonu Nedeniyle Başvuran Hastaların Değerlendirilmesi. Eurasian J Tox. 2019; 1 (1): 11-14.
Levine, M., O’Connor, A. D., Padilla-Jones, A., et al. Comparison of prothrombin time and aspartate aminotransferase in predicting hepatotoxicity after acetaminophen overdose. Journal of Medical Toxicology. 2016;12(1):100–106. doi: 10.1007/s13181-015-0504-x.
Gökhan Ş. (2016). Asetaminofen. Judith E. Tintinalli (Ed.), Tintinalli's emergency medicine: A comprehensive study guide içinde (s.1246-1252). New York: McGraw-Hill Education.
Smilkstein, M.J., Knapp, G.L., Kulig, K.W., et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: analysis of the national multicenter study (1976 to 1985) N Engl J Med. 1988;319(24):1557.
Daly, F.F., Fountain, J.S., Murray, L., et al: Guidelines for the management of paracetamol poisoning in Australia and New Zealand—explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Med J Aust 2008;188(5):296-301.
Beltrán-Olazábal, A., Martínez-Galán, P., Castejón-Moreno, R., et al. Management of acetaminophen toxicity, a review. Iberoamerican Journal of Medicine. 2019; 1(1):22-8.
Park, B.K., Dear, J.W., Antoine, D.J. Paracetamol (acetaminophen) poisoning. BMJ clinical evidence 2015; 2015: 2101.
Bakhsh, Y.B., Alsulami, T.S., Nasief, B.M., et al. Evaluation of the Role of Emergency Physician in Diagnosis and Management of Acetaminophen in the Emergency Department. Arch Pharma Pract 2019;10(2):24-7.
Heard, K.J. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008:17;359(3):285-92. doi: 10.1056/NEJMct0708278.
Prescott, L.F., Stewart M.J., Proudfoot A.T. Cysteamine or N-acetylcysteine for paracetamol poisoning Br Med J. 1978;1(6116):856-7.
Muñoz Romo, R., M Borobia Pérez, A., A Muñoz, M., et al. Efficient diagnosis and treatment of acute paracetamol poisoning: cost-effectiveness analysis of approaches based on a hospital toxicovigilance program. Emergencias. 2018;30(3):169-176.
Heard, K., Green, J. Acetylcysteine therapy for acetaminophen poisoning. Curr Pharm Biotechnol 2012;13(10): 1917-23.
Green, J.L., Heard K.J., Reynolds K.M. et al. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: a systematic review and meta-analysis." Western Journal of Emergency Medicine 2013;14(3):218-226.
Zyoud, S.H., Awang, R., Sulaiman, S.A. : Reliability of the reported ingested dose of acet¬aminophen for predicting the risk of toxicity in acetaminophen overdose patients. Pharmacoepidemiol Drug Saf 2012;21: 207-13.
Klein-Schwartz, W., Doyon, S. : Intravenous acetylcysteine for the treatment of acetaminophen overdose. Expert Opin Pharmacother 2011;12(1):119-130.
Martello, J.L., Pummer, T.L., Krenzelok, E.P.: Cost minimization analysis comparing enteral N-acetylcysteine to intravenous acetylcysteine in the management of acute acetaminophen toxicity. Clin Toxicol (Phila) 2010;48(1):79-83.
Bateman, D.N., Dear, J.W., Thomas, S.H.L. : New regimens for intravenous acetylcysteine: where are we now? Clin Toxicol 2016;54(2):75-8.
Yarema, M., Chopra, P., Sivilotti, M.L.A., et al: Anaphylactoid reactions to intravenous N-acetylcysteine during treatment for acetaminophen poisoning. J Med Toxicol 2018;14(2):120-127.
Prescott, L.F., Park, J., Ballantyne, A., et al. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet. 1977;2:432–4.
Wilkes, J.M., Clark, L.E., Herrera, J.L. : Acetaminophen overdose in pregnancy. South Med J 2005;98(11):1118-22.
Gosselin, S., Juurlink, D.N., Kielstein, J.T., et al. Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2014;52(8):856-67. doi:10.3109/15563650.2014.946994.
Rumack, B.H., Bateman, D.N. Acetaminophen and acetylcysteine dose and duration: past, present and future. Clin Toxicol (Phila) 2012;50(2): 91-98.
Whyte, I.M., Francis, B., Dawson, A.H. Safety and efficacy of intravenous N-acetylcystine for acetaminophen overdose: analysis of the Hunter Area Toxicity service (HATS) Database. Curr Med Res Opin. 2007;23:2359–2368. doi: 10.1185/030079907X219715.
Hodgman, M..J., Garrard, A.R. A review of acetaminophen poisoning. Crit Care Clin. 2012; 28: 499-516.
Prescott, L.F., Illingworth, R.N., Critchley, J.A., et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J. 1979;2:1097–1100. doi: 10.1136/bmj.2.6198.1097.
Chiew, A.L., Gluud, C., Brok, J., Buckley, N.A. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev. 2018;2(2):CD003328. doi: 10.1002/14651858.CD003328.pub3.
Mazer, M., Perrone, J. Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management. J Med Toxicol. 2008;4(1):2-6. doi: 10.1007/BF03160941..
Dargan, P.I., Jones, A.L. Acetaminophen poisoning: an update for the intensivist. Crit Care. 2002;6(2):108-10. doi: 10.1186/cc1465. Epub 2002 Mar 14. PMID: 11983032; PMCID: PMC137288.
Jones, A.L., Dargan, P.I. Over the counter analgesics: a toxicological perspective. Am J Ther. 2002;9(3):245-57.
Ellis, A., Wendon, J. Circulatory, respiratory, cerebral and renal derangements in acute liver failure: pathophysiology and management. Semin Liv Dis. 1996;16:379–388.
Köseoğlu, H., Ersoy, O. Karaciğer Hastalıklarında N-asetil Sistein Kullanımı. Güncel Gastroenteroloji, 2014:18(1),119-124.
Sivilotti, M.L., Yarema, M.C., Juurlink, D.N., et al: A risk quantification instrument for acute acetaminophen overdose patients treated with N-acetylcysteine. Ann Emerg Med 2005;46(3): 263-71.
Mitchell, I., Bihari, D., Chang, R., et al: Early identification of patients at risk from acetaminophen-induced acute liver failure. Crit Care Med 1998; 26(2): 279-84.
Schmidt, L.E., Dalhoff, K. : Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002;36(3): 659-65.
Mehrpour, O., Shadnia, S., Sanaei-Zadeh, H. : Late extensive intravenous administration of N-acetylcysteine can reverse hepatic failure in acetaminophen overdose. Hum Exp Toxicol 2011;30(1):5154.